natgillin/translations-raw huggingface dataset:
General Zomarist is not a substitute for insulin in insulin-requiring patients and should not be used in patients with type 1 diabetes.
Splošno Zdravilo Zomarist ne more nadomestiti zdravljenja z insulinom pri bolnikih, ki potrebujejo insulin, in se ga ne sme uporabljati pri bolnikih z diabetesom tipa 1.
Renal impairment
- vsaj enkrat na leto pri bolnikih z normalnih delovanjem ledvic,
- at least once a year in patients with normal renal function
- vsaj dvakrat do štirikrat na leto pri bolnikih koncentracijami kreatinina v serumu na zgornji meji
- at least two to four times a year in patients with serum creatinine levels at the upper limit of
normalnih vrednosti in pri starejših bolnikih.
Hepatic impairment Patients with hepatic impairment, including those with pre-treatment ALT or AST > 3x ULN, should not be treated with Zomarist (see sections 4.2, 4.3 and 4.8).
Okvara jeter Zdravilo Zomarist se ne sme uporabljati pri bolnikih z okvaro jeter, vključno z bolniki, ki imajo pred zdravljenjem vrednosti ALT ali AST nad 3- kratno zgornjo mejo normalnih vrednosti (glejte poglavja 4. 2, 4. 3 in 4. 8).
Should an increase in AST or in ALT of 3x ULN or greater persist, withdrawal of Zomarist therapy is recommended.
Če zvišanje AST ali ALT na ali nad 3- kratno zgornjo mejo normalnih vrednosti (ULN - upper limit of normal) vztraja, je priporočena prekinitev zdravljenja z zdravilom Zomarist.
Metformin is contraindicated in patients with heart failure, therefore Zomarist is contraindicated in this patient population (see section 4.3).
Metformin je kontraindiciran pri bolnikih s srčnim popuščanjem, zato je tudi zdravilo Zomarist kontraindicirano za to skupino bolnikov (glejte poglavje 4. 3).
Surgery As Zomarist contains metformin, the treatment should be discontinued 48 hours before elective surgery with general anaesthesia and should not usually be resumed earlier than 48 hours afterwards.
Operacijski poseg Zdravilo Zomarist vsebuje metformin, zato je treba zdravljenje z njim prekiniti 48 ur pred načrtovanim operacijskim posegom s splošno anestezijo, ponovno pa se ga sme uvesti šele 48 ur po posegu.
Therefore, due to the metformin active substance, Zomarist should be discontinued prior to, or at the time of, the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Ker zdravilo Zomarist vsebuje zdravilno učinkovino metformin, ga je treba ukiniti pred preiskavo ali v času preiskave, ponovno pa se ga sme uvesti šele 48 ur po preiskavi in sicer samo v primeru, da ponovno vrednotenje pokaže normalno delovanje ledvic (glejte poglavje 4. 5).
4 There have been no formal interaction studies for Zomarist.
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij 4 Formalnih študij medsebojnega delovanja zdravila Zomarist z drugimi zdravili niso opravili.
Vildagliptin Vildagliptin has a low potential for interactions with co-administered medicinal products.
Vildagliptin Vildagliptin ima le majhno možnost medsebojnega delovanja z drugimi sočasno uporabljenimi zdravili.
Metformin Combinations not recommended There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Zomarist (see section 4.4).
Metformin Kombinacije, ki niso priporočene Zaradi metformina, zdravilne učinkovine v zdravilu Zomarist, obstaja pri akutni zastrupitvi z alkoholom (še posebno v primerih stradanja, podhranjenosti ali jetrne insuficience), povečano tveganje za laktacidozo (glejte poglavje 4. 4).
5 There are no adequate data from the use of Zomarist in pregnant women.
Ni zadostnih podatkov o uporabi zdravila Zomarist pri nosečnicah.
Due to both the potential risk of neonate hypoglycaemia related to metformin and the lack of human data with vildagliptin, Zomarist should not be used during lactation (see section 4.3).
Tako zaradi potencialnega tveganja, da bi pri novorojenčku zaradi metformina prišlo do hipoglikemije, kot tudi zaradi pomanjkanja podatkov o vildagliptinu pri ljudeh, se zdravila Zomarist ne sme uporabljati v obdobju dojenja (glejte poglavje 4. 3).
There have been no therapeutic clinical trials conducted with Zomarist.
Terapevtskih kliničnih študij z zdravilom Zomarist niso izvajali.
However, bioequivalence of Zomarist with co-administered vildagliptin and metformin has been demonstrated (see section 5.2).
Dokazali pa so bioekvivalenco zdravila Zomarist s sočasno uporabljanima vildagliptinom in metforminom (glejte poglavje 5. 2).
Frequencies are defined as very common (≥1/10); common (≥1/100, < 1/10); uncommon (≥1/1,000, < 1/100); rare (≥1/10,000, < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Pogostnosti so definirane kot: zelo pogosti (≥1/ 10), pogosti (≥1/ 100, < 1/ 10), občasni (≥1/ 1. 000, < 1/ 100), redki (≥1/ 10. 000, < 1/ 1. 000), zelo redki (< 1/ 10. 000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Table 1
6 Preglednica 1
Common Uncommon
pogosti pogosti pogosti občasni Bolezni prebavil
Gastrointestinal disorders
tremor glavobol omotičnost utrujenost
In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% (7 of 1,855) of patients treated with vildagliptin 100 mg daily compared to 0.2% (2 of 1,082) of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.
V študijah z monoterapijo, kontroliranih s primerjalnim zdravilom, so o hipoglikemiji poročali občasno, pri 0, 4% bolnikov (pri 7 od 1. 855 bolnikov), ki so prejemali 100 mg vildagliptina dnevno, v
In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was administered as monotherapy (-0.3 kg and -1.3 kg for vildagliptin and placebo, respectively).
Telesna masa se v kliničnih preskušanjih ni bistveno spremenila od izhodiščne: pri jemanju 100 mg vildagliptina v monoterapiji se je zmanjšala za 0, 3 kg, pri uporabi vildagliptina skupaj s placebom pa se je zmanjšala za 1, 3 kg.
Decrease of vitamin B 12 absorption and lactic acidosis*
zmanjšanje absorpcije vitamina B 12 in laktacidoza *
At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), AST, C-reactive protein (CRP) and myoglobin levels.Three other subjects experienced oedema of the feet, with paraesthesia in two cases.
Pri treh drugih osebah je prišlo do otekanja stopal, v dveh primerih s parestezijo.
Management The most effective method of removing metformin is haemodialysis.
Obravnava Hemodializa je najučinkovitejši način odstranjevanja metformina.
8 Vildagliptin, a member of the islet enhancer class, is a potent and selective dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Vildagliptin iz skupine spodbujevalcev Langerhansovih otočkov je močan in selektiven zaviralec dipeptidil peptidaze 4 (DPP- 4).
Vildagliptin added to patients whose glycaemic control was not satisfactory despite treatment with metformin monotherapy resulted after 6-month treatment in additional statistically significant mean reductions in HbA 1c compared to placebo (between group differences of -0.7% to -1.1% for vildagliptin 50 mg and 100 mg, respectively).
Vildagliptin, ki so ga dodajali bolnikom, pri katerih glikemija ni bila zadovoljivo urejena kljub zdravljenju z metforminom v monoterapiji, je po 6- mesečnem zdravljenju povzročil dodatno statistično značilno povprečno znižanje HbA 1c v primerjavi s placebom (razlika med skupinama - 0, 7% za odmerek 50 mg vildagliptina in - 1, 1% za odmerek 100 mg vildagliptina).
The proportion of patients who achieved a decrease in HbA 1c of ≥ 0.7% from baseline was statistically significantly higher in both vildagliptin plus metformin groups (46% and 60%, respectively) versus the metformin plus placebo group (20%).
Delež bolnikov, pri katerih je prišlo do znižanja HbA 1c za ≥ 0, 7% od izhodiščne vrednosti, je bil v obeh skupinah s kombinacijo vildagliptina in metformina statistično značilno večji (46% oziroma 60%) v primerjavi s skupino, ki je prejemala metformin in placebo (20%).
Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA- (Homeostasis Model Assessment–), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test.
Zdravljenje z vildagliptinom v odmerkih 50- 100 mg dnevno je pri bolnikih z diabetesom tipa 2 pomembno izboljšalo vrednosti kazalcev delovanja beta celic, vključno z modelom ocene homeostaze HOMA- β, razmerjem med proinsulinom in insulinom ter merjenjem odzivnosti beta celic po obroku s pogostim vzorčenjem.
glycogenolysis;
9
9 The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the long- term benefit of intensive blood glucose control in type 2 diabetes.
V prospektivni randomizirani študiji UKPDS (UK Prospective Diabetes Study - Britanska prospektivna študija diabetesa) so ugotovili dolgoročno koristnost intenzivnega uravnavanja koncentracije glukoze pri diabetesu tipa 2.
Zomarist Absorption Bioequivalence has been demonstrated between Zomarist at three dose strengths (50 mg/500 mg, 50 mg/850 mg and 50 mg/1000 mg) versus free combination of vildagliptin and metformin hydrochloride tablets at the corresponding doses.
Zdravilo Zomarist Absorpcija Za zdravilo Zomarist so dokazali bioekvivalenco treh jakosti (50 mg/ 500 mg, 50 mg/ 850 mg in 50 mg/ 1000 mg) s kombinacijo ločenih tablet vildagliptina in metforminijevega klorida v skladnih odmerkih.
The rate and extent of absorption of metformin from Zomarist 50 mg/1000 mg were decreased when given with food as reflected by the decrease in C max by 26%, AUC by 7% and delayed T max (2.0 to 4.0 h).
Hitrost in obseg absorpcije metformina iz zdravila Zomarist 50 mg/ 1000 mg pa sta bili pri jemanju s hrano zmanjšani, kar se je odražalo na znižanju C max za 26%, zmanjšanju AUC za 7% in na podaljšanem T max (2, 0 do 4, 0 ure).
Vildagliptin Absorption Following oral administration in the fasting state, vildagliptin is rapidly absorbed with peak plasma concentrations observed at 1.7 hours.
Vildagliptin Absorpcija Po peroralni aplikaciji na tešče se vildagliptin hitro absorbira in doseže najvišje koncentracije v plazmi po 1, 7 ure.
Administration of vildagliptin with food resulted in a decreased C max (19%) compared to dosing in the fasting state.
Zaradi uživanja vildagliptina skupaj s hrano se je znižala C max (19%) v primerjavi z odmerjanjem na tešče.
Distribution The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells.
10 Vildagliptin se v majhni meri veže na proteine v plazmi (9, 3%) in se enakomerno porazdeli med plazmo in eritrocite.
10 Elimination Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose was recovered in the faeces.
Izločanje Po peroralni aplikaciji s 14C označenega vildagliptina se je približno 85% odmerka izločilo z urinom, 15% odmerka pa so našli v blatu.
Linearity / non-linearity The C max for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.
Linearnost / nelinearnost C max vildagliptina in površina pod krivuljo časovne porazdelitve koncentracij v plazmi (AUC) sta se v okviru terapevtskih odmerkov povečevali približno sorazmerno z velikostjo odmerka.
In subjects with mild, moderate, or severe renal impairment, systemic exposure to vildagliptin was increased (C max 8-66%; AUC 32-134%) and total body clearance was reduced compared to subjects with normal renal function.
Pri bolnikih z blago, zmerno ali hudo okvaro ledvic je bila izpostavljenost vildagliptinu večja (C max 8- 66%; AUC 32- 134%), celotni telesni očistek pa je bil manjši v primerjavi z osebami z normalnim delovanjem ledvic.
Metformin Absorption After an oral dose of metformin, the maximum plasma concentration (C max) is achieved after about 2.5 h..
Metformin Absorpcija Po peroralni aplikaciji metformin doseže najvišjo koncentracijo v plazmi po približno 2, 5 ure (C max).
At the usual metformin doses and dosing schedules, steady state plasma concentrations are reached within 24-48 h and are generally less than 1 µg/ml.
Pri običajnih odmerkih in shemah odmerjanja se plazemske koncentracije v stanju dinamičnega ravnovesja dosežejo v 24- 48 urah, večinoma pa so nižje
In controlled clinical trials, maximum metformin plasma levels (C max) did not exceed 4 µg/ml, even at maximum doses.
V kontroliranih kliničnih preskušanjih najvišje koncentracije metformina v plazmi (C max) niso presegale 4 µg/ ml niti pri najvišjih odmerkih.
The mean volume of distribution (V d) ranged between 63-276 litres.
Povprečni volumen porazdelitve (V d) je bil v okviru 63- 276 litrov.
11 Metformin is eliminated by renal excretion.
Izločanje Metformin se izloča preko ledvic.
Vildagliptin Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7- fold human exposure based on C max).
Vildagliptin Pri psih so opažali upočasnjeno prevajanje impulzov v srcu, pri tem je bil odmerek brez učinka 15 mg/ kg (kar pomeni izpostavljenost, ki je 7- krat večja od izpostavljenosti pri človeku glede na C max).
No increases in tumour incidence attributable to vildagliptin were observed.
Pri tem niso opažali zvišanih incidenc tumorjev, ki bi jih lahko pripisali
12 Non-clinical data on metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.
Metformin Neklinični podatki o metforminu na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
Not all pack sizes and tablet strengths may be marketed.
13 Na trgu ni vseh navedenih pakiranj in jakosti tablet.
Zomarist 50 mg/1000 mg film-coated tablets
Zomarist 50 mg/ 1000 mg filmsko obložene tablete
Adults Based on the patient’s current dose of metformin, Zomarist may be initiated at either the 50 mg/850 mg or 50 mg/1000 mg tablet strength twice daily, one tablet in the morning and the other in the evening.
Odrasli Glede na odmerek metformina, ki ga je bolnik uporabljal do tedaj, je mogoče začeti z uporabo zdravila Zomarist bodisi jakosti 50 mg/ 850 mg ali 50 mg/ 1000 mg dvakrat dnevno in sicer eno tableto zjutraj, drugo pa zvečer.
Additional information on special populations Renal impairment Zomarist should not be used in patients with creatinine clearance < 60 ml/min (see sections 4.3, 4.4 and 5.2).
Dodatni podatki o posebnih skupinah bolnikov Okvara ledvic Bolniki z očistkom kreatinina < 60 ml/ min ne smejo uporabljati zdravila Zomarist (glejte poglavja 4. 3, 4. 4 in 5. 2).
15 Hepatic impairment Zomarist should not be used in patients with hepatic impairment, including those with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) (see sections 4.3, 4.4 and 4.8).
15 3- kratno zgornjo mejo normalnih vrednosti (upper limit of normal - ULN) (glejte poglavja 4. 3, 4. 4 in 4. 8).
 Hypersensitivity to the active substances or to any of the excipients  Diabetic ketoacidosis or diabetic pre -coma  Renal failure or renal dysfunction defined as creatinine clearance < 60 ml/min (see section 4.4)  Acute conditions with the potential to alter renal function, such as:
- ledvična odpoved oziroma moteno delovanje ledvic, opredeljeno z očistkom kreatinina

- - -
17 There have been no formal interaction studies for Zomarist.
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij 17 Formalnih študij medsebojnega delovanja zdravila Zomarist z drugimi zdravili niso opravili.
18 There are no adequate data from the use of Zomarist in pregnant women.
Ni zadostnih podatkov o uporabi zdravila Zomarist pri nosečnicah.
19 Table 1
19 Preglednica 1
22 In humans, independently of its action on glycaemia, metformin has favourable effects on lipid metabolism.
Metformin ima pri ljudeh neodvisno od delovanja na koncentracijo glukoze v krvi ugoden vpliv na presnovo lipidov, kar se je pokazalo pri uporabi terapevtskih odmerkov v srednje dolgih in dolgotrajnih kontroliranih kliničnih študijah.
Distribution The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells.
23 Vildagliptin se v majhni meri veže na proteine v plazmi (9, 3%) in se enakomerno porazdeli med plazmo in eritrocite.
Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent, and accordingly the metabolic clearance of vildagliptin is not anticipated to be affected by co-
Vildagliptin se ne presnavlja z encimi CYP 450 v zaznavni meri.
23 medications that are CYP 450 inhibitors and/or inducers.
Glede na to ni pričakovati, da bi na presnovni očistek vildagliptina vplivala sočasna uporaba zdravil, ki so zaviralci in/ ali induktorji encimov CYP 450.
Metformin Absorption After an oral dose of metformin, the maximum plasma concentration (T max) is achieved after about 2.5 h..
Metformin Absorpcija Po peroralni aplikaciji metformin doseže najvišjo koncentracijo v plazmi po približno 2, 5 ure (C max).
24 Metabolism Metformin is excreted unchanged in the urine.
Presnova Metformin se izloča z urinom v nespremenjeni obliki.
Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses ≥ 20 mg/kg/day (approximately 3 times human AUC
Pri odmerku ≥ 20 mg/ kg/ dan (kar približno ustreza 3- kratni izpostavljenosti AUC pri človeku pri odmerku 100 mg) so opažali luskavost in luščenje kože, kraste in ranice na repu z ustreznimi histopatološkimi spremembami.
Not all pack sizes and tablet strengths may be marketed.
26 Na trgu ni vseh navedenih pakiranj in jakosti tablet.
PSURs The PSUR cycle of Zomarist will correspond to the one attributed to the cross-referred product, Eucreas, until otherwise specified.
Periodična poročila o varnosti zdravila (PSUR) Periode za predložitev periodičnih poročil o varnosti zdravila Zomarist se bodo ujemale s periodami, ki so določene za referenčno zdravilo Eucreas, dokler ni zahtevano drugače.
Zomarist 50 mg/850 mg film-coated tablets vildagliptin/metformin hydrochloride
Zomarist 50 mg/ 850 mg filmsko obložene tablete vildagliptin/ metforminijev klorid
Zomarist 50 mg/1000 mg film-coated tablets vildagliptin/metformin hydrochloride
Zomarist 50 mg/ 1000 mg filmsko obložene tablete vildagliptin/ metforminijev klorid
Zomarist 50 mg/850 mg film-coated tablets Zomarist 50 mg/1000 mg film-coated tablets
Zomarist 50 mg/ 850 mg filmsko obložene tablete Zomarist 50 mg/ 1000 mg filmsko obložene tablete
What Zomarist is and what it is used for 2.
Kaj je zdravilo Zomarist in za kaj ga uporabljamo 2.
Before you take Zomarist 3.
Kaj morate vedeti, preden boste vzeli zdravilo Zomarist 3.
How to take Zomarist 4.
Kako jemati zdravilo Zomarist 4.
How to store Zomarist 6.
Shranjevanje zdravila Zomarist 6.
WHAT ZOMARIST IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO ZOMARIST IN ZA KAJ GA UPORABLJAMO
The active substances of Zomarist belong to a group of medicines called “oral antidiabetics”.
Zdravilni učinkovini v zdravilu Zomarist sodita v skupino zdravil, ki se imenujejo “ peroralni antidiabetiki ”.
This type of diabetes is also known as non- insulin-dependent diabetes mellitus.
Zdravilo Zomarist se uporablja za zdravljenje bolnikov z diabetesom tipa 2, ki se imenuje tudi od insulina neodvisna sladkorna bolezen.
Zomarist contains two active substances called vildagliptin and metformin.
Zdravilo Zomarist vsebuje dve zdravilni učinkovini, ki se imenujeta vildagliptin in metformin.
BEFORE YOU TAKE ZOMARIST
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO ZOMARIST
Do not take Zomarist
Ne jemljite zdravila Zomarist
Zomarist (listed in section 6).
Zomarist (s seznama v poglavju 6).
Please also see information about this in section “Take special care with Zomarist”.
kateri v žilo vbrizgajo barvilo), informacije o tem dobite tudi pod naslovom “ Bodite posebno pozorni pri uporabi zdravila Zomarist ”;
Take special care with Zomarist Stop taking this medicine and talk to your doctor if you experience one or more of the following symptoms which may be related to a condition called “lactic acidosis”:
Bodite posebno pozorni pri uporabi zdravila Zomarist Če pride do enega ali več spodaj navedenih simptomov, ki so lahko povezani z zapletom, imenovanim “ laktacidoza ”, prenehajte jemati zdravilo in se posvetujte s svojim zdravnikom:
If you have previously taken Galvus (vildagliptin) or Zomarist but had to stop taking it because of side effects (liver disease), you should not take Zomarist again.
Če ste zdravilo Galvus (vildagliptin) ali Zomarist že jemali, pa ste ga prenehali zaradi stranskih neželenih učinkov (bolezni jeter), ga ne smete ponovno jemati.
A test to determine your liver function will be performed before the start of Zomarist treatment, at three-month intervals for the first year and periodically thereafter.
Pred začetkom zdravljenja z zdravilom Zomarist boste opravili preiskavo delovanja jeter, med zdravljenjem pa boste v prvem letu opravljali kontrolne preiskave na tri mesece in kasneje le še občasno.
Elderly patients (65-74 years) taking Zomarist should have their kidney function monitored regularly.
Pri starejših bolnikih (65- 74 let), ki jemljejo zdravilo Zomarist, je treba redno spremljati delovanje ledvic.
Zomarist is not recommended for patients aged 75 years or older.
Uporaba zdravila Zomarist ni priporočena za bolnike, ki so stari 75 let ali več.
Avoid alcohol while taking Zomarist since alcohol may increase the risk of lactic acidosis (please see section “Possible side effects”).
S tem boste zmanjšali možnost želodčnih težav.
48 Pregnancy and breast-feeding
48 V obdobju jemanja zdravila Zomarist se izogibajte uživanju alkohola, ker alkohol lahko poveča tveganje za laktacidozo (glejte poglavje “ Možni neželeni učinki ”).
- Do not use Zomarist if you are breast-feeding.
- Če dojite, ne smete uporabljati zdravila Zomarist.
HOW TO TAKE ZOMARIST
KAKO JEMATI ZDRAVILO ZOMARIST
Always take Zomarist exactly as your doctor has told you.
Pri jemanju zdravila Zomarist natančno upoštevajte zdravnikova navodila.
How much to take The amount of Zomarist that people have to take varies depending on their condition.
Koliko zdravila vzeti Koliko zdravila Zomarist morajo ljudje jemati, je odvisno od njihove bolezni.
Your doctor will tell you exactly the dose of Zomarist to take.
Zdravnik vam bo natančno povedal, kakšen odmerek zdravila Zomarist morate jemati.
If you take more Zomarist than you should If you take too many Zomarist tablets, or if someone else takes your tablets, talk to a doctor or pharmacist immediately.
Če ste vzeli večji odmerek zdravila Zomarist, kot bi smeli Če ste vzeli preveč tablet zdravila Zomarist ali če kdo drug vzame vaše tablete, se takoj obrnite na zdravnika ali farmacevta.
If you forget to take Zomarist If you forget to take a tablet, take it with your next meal unless you are due to take one then anyway.
Če ste pozabili vzeti zdravilo Zomarist Če ste pozabili vzeti tableto, jo vzemite z naslednjim obrokom, razen če je že čas, da vzamete naslednjo tableto.
If you stop taking Zomarist Do not stop taking Zomarist unless your doctor tells you to.
Če ste prenehali jemati zdravilo Zomarist Ne prenehajte jemati zdravila Zomarist, če vam tega ne naroči zdravnik.
Like all medicines, Zomarist can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Zomarist neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.